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A chimeric protein-based malaria 
vaccine candidate induces robust T 
cell responses against Plasmodium 
vivax MSP119
Jairo Andres Fonseca1,2, Monica Cabrera-Mora1, Balwan Singh1, Joseli Oliveira-Ferreira3,  
Josué da Costa Lima-Junior3, J. Mauricio Calvo-Calle4, Jose Manuel Lozano5 & 
Alberto Moreno1,2
The most widespread Plasmodium species, Plasmodium vivax, poses a significant public health threat. 
An effective vaccine is needed to reduce global malaria burden. Of the erythrocytic stage vaccine 
candidates, the 19 kDa fragment of the P. vivax Merozoite Surface Protein 1 (PvMSP119) is one of the 
most promising. Our group has previously defined several promiscuous T helper epitopes within the 
PvMSP1 protein, with features that allow them to bind multiple MHC class II alleles. We describe here 
a P. vivax recombinant modular chimera based on MSP1 (PvRMC-MSP1) that includes defined T cell 
epitopes genetically fused to PvMSP119. This vaccine candidate preserved structural elements of the 
native PvMSP119 and elicited cytophilic antibody responses, and CD4+ and CD8+ T cells capable of 
recognizing PvMSP119. Although CD8+ T cells that recognize blood stage antigens have been reported 
to control blood infection, CD8+ T cell responses induced by P. falciparum or P. vivax vaccine candidates 
based on MSP119 have not been reported. To our knowledge, this is the first time a protein based 
subunit vaccine has been able to induce CD8+ T cell against PvMSP119. The PvRMC-MSP1 protein was 
also recognized by naturally acquired antibodies from individuals living in malaria endemic areas with 
an antibody profile associated with protection from infection. These features make PvRMC-MSP1 a 
promising vaccine candidate.
Plasmodium vivax, the most widespread species of Plasmodium, is responsible for 15 million cases of malaria 
annually1. Most of the funding and resourcing for malaria research have been allocated to P. falciparum on the 
basis that this species is the only human malaria parasite associated with severe disease. Nonetheless, recent 
reports have shown that P. vivax infections are responsible for severe clinical outcomes2. Importantly, several 
strategies used to control P. falciparum may not be effective against P. vivax malaria since this parasite exhibits 
unique characteristics that make its transmission more efficacious than that of P. falciparum3. This effect has been 
observed in the use of Insecticide Treated Nets (ITN) which exhibit lower efficacy for the prevention of vivax 
malaria4. Additionally, the emergence of P. vivax resistance to primaquine5 is a major concern in the field as this 
is the only medication available to cure P. vivax infection. The need for an effective P. vivax vaccine is, therefore, 
a public health priority.
The release of new merozoites during the blood stage infection is the main event in the pathophysiology of 
malaria6. Of the Plasmodium blood stage antigens studied, MSP1 is one of the best-characterized malaria vac-
cine candidates. MSP1 is part of a major complex that makes up most of the merozoite surface7. The merozoites 
released from the schizont exhibit a ~200 kDa MSP1-precursor that is cleaved into several fragments that have 
been characterized in P. falciparum. Of these fragments, the C-terminal MSP1-42 kDa fragment remains on the 
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merozoite surface as a dimer attached through a glycosylphosphatidylinositol (GPI) anchor. At the initiation of 
RBC invasion, the MSP142 kDa fragment is further processed producing two products MSP133 and MSP119, with 
MSP119 remaining on the parasite surface as a monomer to provide the signal for the parasite to start intracellular 
development7.
Antibodies against MSP1, and in particular to MSP119, can block erythrocyte invasion and replication 
in vitro8, protect against parasitemia and malarial anemia9,10 and lyse merozoites via complement-mediated inhi-
bition11. Despite being able to induce of humoral immunity the MSP119 fragment is poorly recognized by T 
cells12,13 due to several disulfide bridges which reduce antigen processing and presentation14. In contrast, MSP133 
specific CD4+ T cells have shown to be involved in protection in the murine model via IFN-γ production, and 
induction of cytophilic antibodies15,16. These features have been confirmed in humans as CD4+ T cells able to 
recognize blood stage antigens have been linked to protection17.
Although a cytotoxic response against MSP1 has not been clearly associated with protection, blood stage 
antigen specific CD8+ T cells are elicited after infection18. In the murine model, antigens expressed by P. berghei 
blood stages are processed and cross-presented by CD8α DCs to stimulate CD8+ T cells19. In humans, CD8+ 
T cells induced after vaccination with viral vectors expressing P. falciparum MSP142 can prolong the prepatent 
period, by controlling the parasite in the liver, since liver schizonts express MSP120.
Despite promising results with P. falciparum antigens, P. vivax blood stage vaccine candidates have not been 
tested in clinical trials. Preclinical trials in non-human primates have been reported for PvMSP1 based vaccines, 
showing partial protection with an immunogenicity dependent on the adjuvant used21–23. Therefore, more studies 
are required to obtain a safe, highly immunogenic PvMSP1 formulation.
In previous studies, we defined several CD4+ T cell epitopes within the native PvMSP1 with features of pro-
miscuous T cell epitopes (i.e. epitopes capable of binding to a broad range of MHC class II alleles)24. Synthetic 
peptides representing these T cell epitopes were successfully recognized by lymphocytes from individuals 
naturally infected with P. vivax24. To further characterize these epitopes, we designed a P. yoelii recombinant 
modular chimera (PyRMC-MSP1) that included the orthologous sequences of the promiscuous T cell epitopes 
identified in P. vivax which were assembled in tandem and genetically fused to the PyMSP119 protein fragment. 
Proof-of-concept studies demonstrated that the inclusion of promiscuous T cell epitopes increased the immu-
nogenicity and efficacy against hyperparasitemia and severe anemia induced by two different P. yoelii strains9.
Based on that evidence, we designed a P. vivax recombinant modular chimera based on MSP1 (PvRMC-MSP1) 
including the five most promiscuous T cell epitopes previously identified using functional assays24. These pro-
miscuous T cell epitopes were arrayed in tandem conformation as described for P. yoelii9 and genetically fused 
to an elongated PvMSP119 fragment (which includes two predicted T helper epitopes present in MSP133)9. 
PvRMC-MSP1 exhibits a complex tertiary structure while preserving the MSP119 structural features. When 
administered in a formulation with Montanide ISA 51, the PvRMC-MSP1 protein is able to induce cytophilic 
antibody responses in the two different mouse strains tested. Importantly, PvRMC-MSP1 can elicit both CD4+ 
and CD8+ T cells capable of recognizing MSP119. To our knowledge, this is the first time a protein subunit vac-
cine has been able to induce CD8+ T cells capable of recognizing the 19 kDa fragment of P. vivax MSP1.
Furthermore, we observed in seroprevalence studies in a population naturally exposed to malaria, a high fre-
quency of total IgG responders to PvRMC-MSP1 with a predominantly cytophilic IgG1 response. The responses 
occurred irrespectively of the different HLA haplotypes in the population, suggesting that the PvRMC-MSP1 
recognition is not genetically restricted.
In this report, we present the development and immunogenic characteristics of PvRMC-MSP1, a promising 
P. vivax vaccine candidate that merits further development as a component of a multi-stage malaria vaccine.
Results
Design, expression and biochemical characterization of PvRMC-MSP1. The chimeric recombi-
nant PvRMC-MSP1 protein has been developed based on our proof-of-concept studies with P. yoelii9,24–26. The 
PvMSP1 experimentally defined promiscuous T cell epitopes were arrayed in tandem and genetically fused to 
an extended PvMSP119 that includes two predicted T helper epitopes present in MSP133 (Fig. 1A,B). We have 
previously validated the relevance of using this topology for the design of chimeric proteins to improve the immu-
nogenicity of P. yoelii and P. vivax antigens in murine models9,24–27. The promiscuous T cell epitopes (i.e. T helper 
epitopes able to bind several MHC class II alleles) were experimentally defined in the P. vivax Belem strain by 
peptide binding competition assays and validated using cells collected from naturally infected individuals24.
To characterize the biochemical identity of the recombinant PvRMC-MSP1 protein, a panel of polyclonal 
antibodies generated by immunization with synthetic peptides representing individual T cell epitopes were 
used for western blot analysis (Fig. 1C). The monoclonal antibody 2A10 which recognizes the P. falciparum 
repeats (NANP)n that were used as a carboxyl terminal tag also recognized the chimeric protein (Fig. 1C, 
Supplementary Figure S1). The antibodies showed a single band at the expected relative mobility of ~31 kDa. 
When the SDS-PAGE was performed under reducing conditions, a shift in the mobility was observed for both 
PvRMC-MSP1 and PvMSP119, indicating that the disulfide bonds present in PvMSP119 that are critical for bio-
logical activity are also preserved in PvRMC-MSP1 (Supplementary Figure S2).
In addition to the biochemical assessment, endotoxin levels were also determined using the limulus amebo-
cyte lysate assay. This protein preparation contained 42 endotoxin units (EU)/mg of protein.
Secondary structure elements on PvRMC-MSP1. Given the relevance of the association between 
3D structure and functional activity, we decided to analyze representative secondary structure elements of the 
PvRMC-MSP1 by circular dichroism (CD). This methodology has proven to be helpful quantitatively to esti-
mate secondary structural elements present in polypeptides, independent of their origin. CD experiments were 
www.nature.com/scientificreports/
3Scientific RepoRts | 6:34527 | DOI: 10.1038/srep34527
conducted under different hydrophobic solvent systems, such as water and aqueous 30% TFE (trifluoroethanol), 
to detect stable structural regions in the entire PvRMC-MSP1 conformation28.
PvRMC-MSP1 prepared in water displayed a structure pattern consisting of α -helical conformations 
which were revealed by the presence of two minimal ellipticity values at 208 nm and 222 nm (shown in solid 
black, Fig. 2A). This structure pattern could indicate that the molecule in solution stabilizes in a high percent-
age of alpha-helical segments. When PvRMC-MSP1 was analyzed in a stronger hydrophobic system, a 30% 
Figure 1. Design, expression and functional characterization of PvRMC-MSP1. (A) Schematic 
representation of the recombinant protein reported here. PvRMC-MSP-1 includes five promiscuous T cell 
epitopes interspaced with a GPGPG spacers, enclosed in gray boxes, and genetically fused to the carboxyl 
terminal region of the native sequence that contains EGF domains sequences that are the target of protective 
antibodies. (B) Sequence of the PvRMC-MSP-1 protein. The amino acid sequence is shown in single letter 
code. The carboxyl terminal (H)6 tag provided by the vector was not included in the sequence. Promiscuous 
T cell epitopes are highlighted in gray. (C) Coomassie stain after SDS-PAGE separation, total bacterial lysate 
after induction and purified PvRMC-MSP1 are shown separated on a 4–20% gradient gel (lanes 1 and 2). The 
molecular weight markers (BioRad) are indicated. Western blot analysis of the purified PvRMC-MSP1 (lanes 
3–6) incubated with sera samples from mice immunized with a synthetic peptide representing the T cell epitope 
L158-D177 (lane 3), a synthetic peptide representing the T cell epitope L378-S397 (lane 4), a synthetic peptide 
representing the T cell epitope N78-L97 (lane 5) or the monoclonal antibody 2A10 that recognizes the C-terminal 
tag (NANP)6 (lane 6). (D) Characteristic immunofluorescence pattern of anti-PvRMC-MSP1 IgG antibodies 
from BALB/c mice at a 1:500 dilution on erythrocytes infected with schizonts from P. vivax (Top) or P. coatneyi 
(Bottom). Left panels show anti-PvRMC-MSP1 antibody reactivity using IgG-specific Alexa Fluor 488 goat 
anti-mouse, center panels show parasite nuclei stained with DAPI. Right panels are a merge of the blue and 
green fluorescence channels.
www.nature.com/scientificreports/
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TFE-aqueous solution, the CD profile obtained revealed a strong anti-parallel -β - turn behavior, shown by a 
minimum ellipticity value at 222 nm and a maximum value at 205 nm (shown in red, Fig. 2A). It is well known 
that TFE and other alcohol-derived solvent systems stabilize alpha-helical structure conformations on polypep-
tides29. Remarkably our experiments showed that a preferential β –turn conformation was highly stabilized within 
PvRMC-MSP1 in TFE solution. This structural feature could have an impact on the functional activity of the 
chimeric protein in vivo.
Another important characteristic necessary for the functionality of PvMSP1 based proteins is the conservation 
of the disulfide bridges between the two EGF domains present in the 19 kDa fragment, as the proper conformation 
of the molecule which depends on the formation of these bridges is necessary for the production of protective 
antibodies30. To confirm that PvRMC-MSP1 maintains the MSP119 fragment conformation, we used polyclonal 
antibodies obtained from mice immunized with PvMSP119 and absorbed all the antibodies directed against the 
linear epitopes using an ELISA in which the antigen was PvRMC-MSP1 in a reduced state. After the absorption of 
the linear antibodies, we tested if the post-absorption antibodies which could then be considered “conformational” 
were able to recognize PvRMC-MSP1 in a reduced and a non-reduced state. We observed that the conformational 
antibodies recognized the protein in its conformational state but not when this protein is reduced, confirming that 
PvRMC-MSP1 maintains the structural elements of PvMSP119 (Supplementary Figure S3).
CD data deconvolution. The aim of data deconvolution is to provide a quantitative estimation of the secondary 
structural elements, using the data determined in CD experiments, represented as the amount of protein that 
adopts a given structural profile. This approach allows us to analyze the secondary structural components present 
in the entire PvRMC-MSP1 quantitatively.
Data deconvolution was performed using three different platforms: CDsstr, Continll, and Selcon3. The 
PvRMC-MSP1 chimeric protein was analyzed under high hydrophilic conditions (100% water). CDsstr anal-
ysis produced a profile consisting of 53.0% α -helix, 31.6% β -strand and 15.4% random coil. Using Continll, we 
obtained a profile of 25.7% α -helix, 46.1% β -strand and 28.2% random coil. Selcon3 analysis produced a profile 
that included 25.2% α -helix, 47.6% β -strand and 27.2% random coil. Of these three algorithms, Continll and 
Selcon3 defined a higher percentage of β -turn structural content for PvRMC-MSP1 in water.
When PvRMC-MSP1 CD data was analyzed in a hydrophobic environment (30% TFE-aqueous solution), 
CDsstr analysis produced a profile consisting of 25.0% α -helix, 49.0% β -strand and 26.0% random coil. A com-
position of 25.7% α -helix, 46.1% β -strand and 28.2% random coil was obtained by analysis with Continll, and a 
profile consisting of 25.2% α -helix, 47.6% β -strand and 27.2% random coil was obtained by analysis with Selcon3. 
Unlike our observations under highly hydrophilic conditions, when PvRMC-MSP1 was analyzed in stronger 
hydrophobic conditions all algorithms were in agreement with a β -turn structural conformation. Remarkably, in 
both solvent systems, the amount of randomly organized structures ranged from 22.0% to 28.2% thus the whole 
CD profile in both cases was due to highly structured polyproteins in solution.
Three-dimensional structure predictive models for PvRMC-MSP1 and PvMSP119 chimeric proteins. Molecular 
representations for protein structures, shown as colorful ribbons representing the protein backbones, allow us 
to infer local structural constraints in both PvRMC-MSP1 and PvMSP119 (Fig. 2B). PvRMC-MSP1 displays five 
alpha-helical regions interconnected by more flexible beta-stranded regions. The following alpha-helical regions 
were identified from M1 to L24 for the first, and between F30 to H49, L55 to D74, L80 to S99 for the intermediate three. 
The final alpha helix is larger and closer to the C-terminal from S105 to N124, as observed in Fig. 2B.
Figure 2. PvRMC-MSP1 Molecular modeling and 3D conformations. (A) Secondary structure patterns by 
circular dichroism and data deconvolution with CDsstr, Continll, and Selcon3 of the CDPro software package. 
Solid black lane denotes the secondary structure element profile of PvRMC-MSP1 recorded in water, and 
the solid magenta line indicates the molecule structure recorded in 30% of aqueous TFE. (B) PvRMC-MSP1 
and PvMSP119 predicted-validated 3D structure molecular model. Purple ribbons represent the polypeptide 
backbone α -helical conformations, green and white regions represent highly flexible stretches and the yellow 
and blue zones represent the β -strands and β –turns. In the PvRMC-MSP1 and PvMSP119 structures, the 
(NANP)6 motif is present as the surface accessible to solvent, in yellow color. Arrows denote the N- and 
C-terminal regions of both molecules.
www.nature.com/scientificreports/
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The global 3D structure revealed an anti-parallel-β -strand region anchored to the His-rich C-terminal portion 
of PvRMC-MSP1, which was also evident in the CD experiments. At the N-terminal region of PvRMC-MSP1, 
where the T cell epitopes are located, the 3D structure was revealed to be highly α –helical, while the more flexible 
regions where the GPGPG (Gly-Pro-Gly-Pro-Gly) linkers are located are consistent with β -strand and β -turn 
conformations. The molecular model obtained for PvMSP119 displayed a relevant content of β -strand, β -turns 
and antiparallel-β -strand conformations. These protein features provide high energy and flexible conformations 
to the protein due to the addition of a substantial number of degrees of freedom to the whole molecule (Fig. 2B).
Regarding the quality of computationally predicted protein structures, both data systems were validated by 
using the remote Swiss-Model server for each processed data set corresponding to PvRMC-MSP1 and PvMSP119. 
Ramachandran plot considerations were obtained using Procheck software, which checks the stereochemical 
quality. For PvRMC-MSP1 (290 residues) and PvMSP119 (162 residues) we obtained values of 80% and 60% 
respectively. These data demonstrate a minimal violation of the geometrical and stereochemical parameters in 
the predicted protein structures such as backbone conformation, amino acid side-chain orientation, peptide 
and chemical bonds length, peptide-bond angles and planar groups. Therefore, the whole molecular restraint 
and constraint features were in a desirable statistical range to be considered allowed conformations for both 3D 
molecular structures.
Humoral immune response in mice immunized with PvRMC-MSP1. Anti-protein and anti-peptide 
antibody responses. After the third and final immunization with PvRMC-MSP1, antibody titers against 
PvMSP119 had a mean titer of 7.9 × 105 in BALB/c and 4.1 × 105 in C57BL/6 mice. These titers were similar 
to those obtained after the immunization with the native PvMSP119 (Fig. 3A). We measured the IgG1 and 
IgG2a levels to determine if the inclusion of promiscuous T cell epitopes modified the Th1 or Th2 response pat-
terns. In BALB/c mice, similar IgG2a/IgG1 ratios were observed between the groups of mice immunized with 
PvRMC-MSP1 or PvMSP119, with both ratios indicating a predominantly Th2 response. Meanwhile, C57BL/6 
mice immunized with PvRMC-MSP1 exhibited higher IgG2a/IgG1 ratios when compared to mice immunized 
with PvMSP119, demonstrating that immunization of C57BL/6 mice with PvRMC-MSP1 skewed the response 
towards a Th1 phenotype, which was not the case for vaccination with PvMSP119 (Fig. 3B). We also measured the 
avidity to PvMSP119 in mice immunized with PvRMC-MSP1, as an indicator of the antibodies quality. In BALB/c 
mice, an average of 3.3 M of thiocyanate was required to dissociate 50% of the bound anti-PvMSP119 antibod-
ies elicited by immunization, corresponding to an avidity index of 0.71. Antibodies elicited in C57BL/6 mice 
required an average of 4.5 M of thiocyanate for 50% dissociation, exhibiting an avidity index of 0.87.
We also tested the antibody responses against the amino terminal promiscuous T cell epitopes included in 
PvRMC-MSP1. Immunization with PvRMC-MSP1 elicited significantly higher antibody titers against PvT53 
when compared to the antibody responses elicited by other epitopes in both BALB/c and C57BL/6 mice (Fig. 3C).
We tested sera samples by immunofluorescence assay against P. vivax infected erythrocytes, to assess the 
reactivity of the antibodies induced by immunization with PvRMC-MSP1 against the native protein. Both mice 
strains recognized blood stages with a pattern of fluorescence reported for PvMSP1 (Fig. 1D) with no significant 
differences in antibody titers (p = 0.07). Nonetheless, C57BL/6 mice showed a trend for higher antibody titers 
(Geometrical mean 2.1 × 105) than BALB/c mice (Geometrical mean 5.1 × 104).
Figure 3. Humoral responses induced by PvRMC-MSP1 or PvMSP119. (A) Anti-MSP119 antibody titers 
determined in sera samples (n = 10 per group) collected 20 days after the final immunization with PvRMC-
MSP1 or PvMSP119 (day 60). Bars represent arithmetic mean values for each group. (B) Anti-PvRMC-MSP1 
IgG2a/IgG1 ratio after the immunization with PvRMC-MSP1 (closed bars) and PvMSP119 (open bars) sera 
from both BALB/c and C57BL/6 mice was obtained 20 days after the final immunization (n = 10 per group), 
*p = 0.0104 by Student’s t test. (C) Recognition of the promiscuous T cell epitopes present in PvRMC-MSP1 
by BALB/c (open bars) and C57BL/6 (closed bars) mice 20 days after the final immunization. **p < 0.01 
***p < 0.001 by one-way ANOVA with Bonferroni posttest.
www.nature.com/scientificreports/
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Native and cross-reactive antibody responses. The P. vivax T cell epitopes used in PvRMC-MSP1 were selected 
based on their ability to function as promiscuous epitopes and the high frequency of specific T cells present in 
the peripheral blood of individuals naturally infected with vivax malaria24. Given the phylogenetic similarities 
between Plasmodium vivax and the simian parasites P. cynomolgi and P. coatneyi, and considering the potential 
of using these parasites as surrogate models to test protective efficacy in rhesus macaques, we decided to assess if 
sera samples from BALB/c and C57BL/6 mice immunized with PvRMC-MSP1 cross-react with P. coatneyi MSP1. 
PvRMC-MSP1 promiscuous T cell epitopes had between 70 and 95% homology for the same MSP-1 sequences in 
P. coatneyi and between 85 and 95% for P. cynomolgi MSP-1 (Table 1, Supplementary Table S1). Antibodies derived 
from both strains of immunized mice recognized P. coatneyi blood stage parasites (Fig. 1D), providing additional 
evidence that PvRMC-MSP1 induces antibodies that are capable of recognizing the naturally derived MSP-1 
protein. The PvRMC-MSP1 T cell epitopes can act as universal epitopes given their structural features, including 
a large aromatic or hydrophobic residue in position 1 (Y, F, W, L, I, V, M) and a small, noncharged residue in 
position 6 (S, T, C, A, P, V, I, L, M) (Table 1 underlined)31. This biochemical characteristic known as the P1-P6 
motif was conserved for both P. coatneyi and P. cynomolgi in four of the five promiscuous T cell epitopes and also 
in the MSP133 fragment used in our chimeric protein (Supplementary Table S1). We also determined the protein 
sequence identity of promiscuous T cell epitopes in comparison to five representative P. vivax strains (i.e. Brazil 
I, India VII, Salvador I, North Korea, Mauritania I). The epitopes exhibited a protein identity that ranged from 
90 to 100%. Relevantly, none of the amino acid changes is located in the P1-P6 motif (Supplementary Table S2), 
confirming the highly conserved nature of these epitopes.
Cellular immune responses in mice immunized with PvRMC-MSP1. Cellular responses against 
PvMSP119. At day five after the final immunization, flow cytometry and intracellular cytokine staining were per-
formed to characterize the T cell reactivity induced by vaccination with PvRMC-MSP1 or the native PvMSP119, 
following ex vivo stimulation of splenocytes with PvMSP119. In C57BL/6 mice, there was a significantly higher 
frequency of IFN-γ secreting cells in response to PvMSP119 by both CD4+ (p = 0.047) and CD8+ (p = 0.024) 
T cells in the group immunized with PvRMC-MSP1 when compared to the mice immunized with the native 
PvMSP119 (Fig. 4A,B). In BALB/c mice, the frequency of IFN-γ secreting cells was significantly higher in CD8+ T 
cells (p = 0.037) but not in CD4+ T cell population (p = 0.108) (Fig. 4C,D). There were no significant differences 
in the frequency of IFN-γ secreting cells between the strains in either CD4+ (p = 0.068) and CD8+ (p = 0.395) 
T cells. On the frequency of IL-2 and TNF-α secreting CD4+ T cells, we observed significant differences in the 
production of TNF-α in BALB/c mice (p = 0.024), but there were no other differences between the groups or the 
strains after the stimulation with PvMSP119. Importantly, in both strains, the CD8+ T cells were able to produce 
IL-2 in response to PvMSP119 in a significantly higher proportion after the immunization with PvRMC-MSP1.
Cellular responses against PvRMC-MSP1. We assessed the cellular response to the different components 
of PvRMC-MSP1 using ex vivo stimulation with peptide pools representing the promiscuous T cell epitopes 
(Fig. 5A,B) or PvMSP119 (Fig. 5C,B), (Supplementary Table S3). Following stimulation with the peptides repre-
senting the promiscuous T cell epitopes, BALB/c mice immunized with PvRMC-MSP1 showed a significantly 
higher proportion of IFN-γ and TNF-α secreting CD4+ and CD8+ T cells when compared to mice immunized 
with PvMSP119 (Fig. 5A,B). Although the percentage of IL-2 secreting cells was higher in the CD4+ T cells 
from the PvRMC-MSP1 immunized mice, this difference was not significant. In contrast, CD8+ T cells from 
PvRMC-MSP1 displayed a greater proportion of IL-2 producing cells when compared to the cells from mice 
immunized with the native PvMSP119. The frequency of IFN-γ and IL-2 secreting CD4+ T cells after the stim-
ulation with peptide pools representing PvMSP119 were not significantly different between the immunization 
groups in BALB/c mice (Fig. 5C). Nonetheless, the responses were higher in the PvRMC-MSP1 group (Fig. 5C). 
Importantly after the stimulation with the peptide pools representing PvMSP119, there were a significantly higher 
proportion of CD8+ T cells able to produce all the analyzed cytokines in the PvRMC-MSP1 immunization group 
confirming that unlike the immunization with the native PvMSP119 our chimeric protein improved the recog-
nition of PvMSP119 by CD8+ T cells. We obtained similar results in C57BL/6 mice (Supplementary Figure S4).
Seroepidemiological studies. Frequency and magnitude of Human IgG immune response against PvRMC-MSP1. 
To evaluate the frequency of antibody responses to PvRMC-MSP1 in a naturally exposed population, plasma 
samples collected from 258 individuals living in two areas where P. vivax accounts for more than 70% of the 
clinical cases of malaria were assessed by ELISA. We collected blood samples from rain forest natives who have 
resided in the malaria-endemic region for over 25 years (Ribeirinha) or individuals who were transmigrants 
Promiscuous 
T cell Epitope
Plasmodium vivaxa  
(GenBank XM_001614792.1)
Plasmodium coatneyia,b  
(GenBank BAF74048)
Homology 
(%)
Plasmodium cynomolgia,b  
(GenBank BAI82251)
Homology 
(%)
PvT4 NFVGKFLELQIPGHTDLLHL DFVGKYLELQIPGHANLLHM 75 DFVGKFLELQIPGHTNLLHM 85
PvT6 FNQLMHVINFHYDLLRANVH FNQLMHVVNFNYDLLRAKLN 70 FNQLMHVINFHYDLLRAKLN 85
PvT8 LDMLKKVVLGLWKPLDNIKD LDMLKKVVLGYRKPLDNIKD 90 LDMLKKVVLGYRKPLDNIKD 90
PvT19 LEYYLREKAKMAGTLIIPES LEYYLREKAKMAGTLIAPES 95 LEYYLREKAKMAGTLITPES 95
PvT53 SKDQIKKLTSLKNKLERRQN SKEHIKKLTSLKNKLERRQN 90 SKEQIKKLTSLKNKLERRQN 95
Table 1.  Amino acid sequence homology between Plasmodium vivax promiscuous T cell epitopes 
included in PvRMC-MSP1 and simian Plasmodium Species. aUnderline Denotes P1-P6 motif. bBold denotes 
amino acid changes from the P. vivax sequence.
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from several non-endemic areas of Brazil, living in the malaria endemic area for the last decade (Colina). The 
prevalence of anti-PvRMC-MSP1 antibodies in the populations studied was 50.4% (130/258 individuals). There 
was a high total IgG reactivity against our chimeric protein as shown by the reactivity indexes (RI) ranging from 
0.08 to 12.3 (Fig. 6A).
PvRMC-MSP1 contains six copies of the P. falciparum NANP repeat sequence as a C-terminal tag for charac-
terization and purification purposes. Since the sera samples collected in the present study belong to individuals 
living in an area where P. falciparum also occurs, it is possible that antibody responses to the CSP repeats can 
also account for the anti-PvRMC-MSP1 reactivity. To study the contribution of antibodies to P. falciparum CSP 
repeats in the response to PvRMC-MSP1, we performed absorption ELISA experiments. PvRMC-MSP1-positive 
antibody samples from 63 randomly selected individuals were pre-incubated with an (NANP)6 synthetic peptide 
before the evaluation of IgG reactivity against PvRMC-MSP1. These experiments showed that only 31.7% of 
Figure 4. T cell responses after immunization with PvRMC-MSP1 or PvMSP119. Five Days after the final 
immunization spleens from BALB/c or C57BL/6 mice immunized with either PvRMC-MSP1 (n = 5 per strain) 
or PvMSP119 (n = 5 per strain) were processed and stimulated with PvMSP119 and the frequency of cytokine-
secreting T cell assessed. Top Panel. CD4+ (A) and CD8+ (B) cytokine secreting T cells in C57BL/6 mice. 
Bottom Panel. CD4+ (C) and CD8+ (D) cytokine secreting T cells in BALB/c mice. Results are presented after 
background subtraction using three technical replicates per sample. Statistical analysis was done using Mann-
Whitney test. *p < 0.05.
Figure 5. T cell responses to the different components of PvRMC-MSP1 in BALB/c mice. Five days after 
the final immunization spleens from BALB/c mice immunized with either PvRMC-MSP1 (n = 5) or PvMSP119 
(n = 5) were processed and stimulated with peptide pools representing the different components of PvRMC-
MSP1 and cytokine-secreting T cells assessed. Top Panel. CD4+ (A) and CD8+ (B) cytokine secreting T cells 
after stimulation with peptide pools representing the promiscuous T cell epitopes present in PvRMC-MSP1. 
Bottom Panel. CD4+ (C) and CD8+ (D) cytokine secreting T cells after stimulation with peptide pools 
representing the PvMSP119 protein fragment present in PvRMC-MSP1. Results are presented after background 
subtraction using three technical replicates per sample. Statistical analysis was done using Mann-Whitney test. 
*p < 0.05 **p < 0.01.
www.nature.com/scientificreports/
8Scientific RepoRts | 6:34527 | DOI: 10.1038/srep34527
the samples were positive against (NANP)6 with a reactivity index (RI) ranging from 0.4 to 2.690 (median 0.85) 
(Supplementary Figure S5). We compared the optical densities of the samples that reacted against PvRMC-MSP1 
before and after the absorption procedure and found no significant differences (Fig. 6B). Although we cannot 
guarantee that this process removed all anti-NANP antibodies, the RI against (NANP)6 after absorption presented 
a very significant decrease (p < 0.0001). Moreover, all 20 individuals who were NANP responders before the 
absorption, became non-responders (Supplementary Figure S5). The results confirm that the antibody reactivity 
reported by PvRMC-MSP1 is not affected by the (NANP)6 tag.
Antibodies from responders were further analyzed to determine the IgG subclass profile (Fig. 6C). The 
cytophilic IgG1 subclass was the predominant type being present in 90% of the samples (Fig. 6C) a proportion 
that was significantly higher when compared to the other subclasses (p < 0.001 by Χ 2 test). When we analyzed 
the levels of specific antibodies as a reactivity index, there was a noteworthy predominance of IgG1 antibodies 
(Fig. 6D).
Relationship between malaria exposure and PvRMC-MSP1 response. To assess whether epidemiological factors 
influence the naturally acquired immune response against PvRMC-MSP1, we correlated different parameters 
of the population with the reactivity indexes of total IgG and the IgG subclasses (Table 2). We did not observe 
a correlation between the age, the time of residence in the malaria endemic area, or the time of residence in 
Rondonia (the population with the highest endemicity of those studied). To assess the effect of malaria history 
in the immune response against PvRMC-MSP1, we correlated the number of past infections and the months 
since the previous infections. We observed that the number of malaria infections contracted in the past showed 
a significant direct correlation with antibody response to PvRMC-MSP1 (r = 0.1750, p = 0.0052), indicating an 
additive effect of the specific immune response acquired. Most importantly the anti-PvRMC-MSP1 antibod-
ies were negatively correlated with the months since the previous infections suggesting a potential role for the 
anti-PvRMC-MSP1 antibodies in protection.
Influence of HLA in IgG response. To determine if antibodies directed against PvRMC-MSP1 were genetically 
restricted, we evaluated the influence of HLA-DRB1* and HLA-DQB1* alleles and haplotypes on the naturally 
acquired IgG response to PvRMC-MSP1. Although 49.9% of the population did not present detectable titers 
of antibodies against PvRMC-MSP1, there does not appear to be a genetic restriction to this antigen, since 
we did not observe any association between the HLA DRB1* or DQB1* alleles and the antibody response to 
PvRMC-MSP1 (Supplementary Table S4).
Figure 6. Antibody recognition of PvRMC-MSP1 by individuals naturally exposed to malaria.  
(A) Reactivity Index in the studied population to the recombinant chimeric protein PvRMC-MSP1. The 
geometric mean of the IgG reactivity index against PvRMC-MSP1 was significantly higher in people with 1 or 
more malaria infections in the year of collection. **p < 0.01 ***p < 0.001 by Mann-Whitney test. (B) IgG titers 
against PvRMC-MSP1 presented as optical densities after absorption of the antibodies against the (NANP)6 
peptide. No significant differences were observed between the optical densities before and after absorption. 
(C) Frequency of IgG subclass responders to the recombinant chimeric protein PvRMC-MSP1 among the IgG 
responders. A χ 2 test was performed to determine the differences between the frequency of IgG1 responders 
compared with all others IgG subclasses. **p < 0.01 ***p < 0.001. (D) Reactivity Index by IgG subtype of the 
samples against PvRMC-MSP1. ***p < 0.001 by one-way ANOVA with Bonferroni’s posttest.
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Discussion
The design of an effective malaria vaccine has proven to be a formidable research challenge. As a target, MSP1 
offers appealing features as it is expressed in both the hepatic and the erythrocytic stages of infection32. Although 
antibodies against this antigen are involved in protection9,10, the protective role of the cellular immune responses 
induced by MSP1 is still unclear. MSP119 is the protein fragment involved in the humoral response, but the 
cellular response induced by the whole MSP1 protein seems to target the MSP133 fragment33. While CD8+ T 
cell epitopes have been described in P. falciparum MSP119, a cellular response against this antigen has not been 
achieved, even when viral vectors are used to deliver this fragment34.
Here, we report the design and characterization of a Recombinant Modular Chimera (RMC) based on 
PvMSP1 in which defined cognate promiscuous T cell epitopes were genetically linked through GPGPG spacers 
to enhance the immunogenicity of PvMSP119. We have previously used this approach in proof of concept stud-
ies using synthetic peptides or recombinant proteins26,27,35. CD data support the rationale for using this protein 
topology. The Ramachandran plot is used as a way to visualize the backbone dihedral angles ψ against ϕ allowed 
for amino acid residues in a protein structure. The plot, therefore, shows the different segments that correspond 
to “core regions” representing the most favorable combinations of ϕ -ψ values. Values higher than 60% are sta-
tistically relevant and are considered “favored or allowed conformations”36. In our particular case, 80% and 60% 
represent the stable protein conformations in solution for both the PvRMC-MSP1 construct and for PvMSP119, 
respectively. Hence, the presence of T cell epitopes in alpha-helical conformation within PvRMC-MSP1 would 
allow stable MHC – antigen – TCR interactions, leading a hydrogen bonding network for the immuno-dominant 
ternary complexes.
The molecular modeling of PvRMC-MSP1 also validated the reported structure of the P. vivax MSP-1197. 
Although the N- terminal domain of the chimeric protein contains distinct structural elements, the C-terminal 
domain assumes the closely packed U-shape conformation characteristic of the P. vivax MSP119. This structural 
feature includes two epidermal growth factor (EGF)-like domains, present in tandem conformation (Fig. 2B). 
Crystallographic data available for P. cynomolgi37 and P. knowlesi38 defined the classical array of disulfide bonds 
in the second EGF-like domain between cysteines 1–3, 2–4, and 5–6 with a second disulfide bond missing in the 
first EGF-like domain. EGF-like domains present within PvRMC-MSP1 are located between amino acids M167 
and V213, and T214 and S258 and contain two anti-parallel beta-strand pairs (Fig. 2B). Relevantly, PvRMC-MSP1 
induced antibodies that are able not only to recognize the recombinant P. vivax MSP119 but the native protein on 
the parasite surface, showing that the recognized epitopes are accessible.
As expected, immunization with PvRMC-MSP1 elicited antibody titers higher than 1 × 105 in two differ-
ent mouse strains after three immunizations. These antibodies were able to recognize our vaccine candidate, a 
recombinant protein representing PvMSP119 and the native protein in P. vivax infected RBCs. Total IgG antibody 
titers induced by PvRMC-MSP1 are similar to those reported for a synthetic protein expressed in Saccharomyces 
cerevisiae formulated in Freund’s adjuvant39. The formulation of PvRMC-MSP1 in Montanide ISA 51 supports 
the fact that the immunogenicity of our formulation is dependent on the inclusion of the T cell epitopes rather 
than on the adjuvant22,39.
The immune response was skewed towards a Th1 profile following immunization of C57BL/6 mice with 
PvRMC-MSP1, as we observed IgG2a/IgG1 ratios higher than one, which was not the case in other PvMSP1 
vaccine candidates39–43. Although high levels of IgG2a were also detected in BALB/c mice, the IgG2a/IgG1 ratio 
suggested a Th2 biased response, which is expected since the genetic regulation of the immune response the 
BALB/c strain favors the production of IL-4 over IFN-γ 44. Even when viral vectors are used to present PfMSP1, 
the IgG2a/IgG1 ratios in BALB/c are still indicative of a Th2 response34. Our results suggest that the help pro-
vided by the promiscuous T cell epitopes enhances the production of cytophilic antibodies. The production of 
cytophilic antibodies by PvRMC-MSP1 is encouraging since the inhibition of red blood cell invasion is correlated 
with the ability of cytophilic antibodies directed against MSP1 to interact with complement11. In addition to the 
ability of PvRMC-MSP1 to elicit the production of cytophilic antibodies in mice, sera samples from humans 
naturally exposed to P. vivax had a high prevalence of cytophilic IgG1 antibodies that recognize PvRMC-MSP1. 
The quality of the antibody response elicited by immunization was also confirmed by the assessment of the higher 
avidity of anti-PvRMC-MSP1 antibodies in C57BL/6 mice. Similarly, phase I clinical studies carried on with a 
long synthetic peptide based on P. falciparum MSP3 have shown that anti-parasite antibody-dependent cellular 
inhibition is related to the antibodies avidity45. These results demonstrate that immunization with PvRMC-MSP1 
could achieve a high avidity cytophilic IgG response that is correlated with protection.
Consistent with the high homology (>70%) between the promiscuous T cell epitopes and the MSP19 frag-
ment included in PvRMC-MSP1 and the simian malaria species P. coatneyi and P. cynomolgi, we observed that 
Epidemiological Factor
Relation with Anti-PvRMC-
MSP1 Antibodies
Spearman (r) p value
Age 0.1112 0.07
Time of residence in malaria endemic area − 0.038 0.53
Time of residence in Rondonia 0.0007 0.99
Number of past malaria infections 0.1795 0.003
Number of months since the last infection −0.3101 <0.0001
Table 2.  Anti-PvRMC-MSP1 antibody prevalence in Brazilian donors.
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antibodies induced by PvRMC-MSP1 were able to recognize P. coatneyi blood stage parasites by IFA. The antibod-
ies recognition of other species confirms that the promiscuous P. vivax T cell epitopes included in PvRMC-MSP1 
are conserved in the simian Plasmodium species and preserve their biochemical features. This feature also demon-
strates the potential of using P. cynomolgi or P. coatneyi in rhesus macaques as a surrogate model to test efficacy as 
P. vivax appears to be a species derived from the Macaca lineage of simian parasites46.
Preclinical trials in NHP have been reported for PvMSP1 based vaccines. PvMSP119 expressed in S. cerevisiae 
linked to two tetanus toxoid promiscuous T-helper epitopes21 induced partial protection in Saimiri boliviensis 
monkeys. However, the immunogenicity of the protein was highly dependent on the adjuvant used in the for-
mulation21,47. This effect was also observed when an MSP119 protein associated to two pan allelic CD4+ T cell 
epitopes was used in Callithrix jacchus, with no evident boosting effect induced by the associated T cell epitopes22. 
Studies using MSP133 in Aotus monkeys have shown a protective efficacy between 50 to 80% according to the 
fragment of the protein used. However, these studies used Freund’s adjuvant, a formulation that is not suitable 
for human use23,48. In another study, recombinant PvMSP1 formulated in Montanide ISA 720 was also able to 
protect Aotus monkeys from an infectious challenge reducing the parasitemia levels in comparison with control 
monkeys49. These studies demonstrate that achieving protection with PvMSP1 is a feasible goal; but further devel-
opment is required to obtain a safe, highly immunogenic formulation.
Studies with recombinant PvMSP119 have shown that this protein is not processed by DCs since the antigen is 
not soluble and remains attached to the parasite during the ring stage following RBC invasion50. In rodent models 
the conserved disulfide bridges, the main structural feature of the native proteins, impede antigen processing 
thereby preventing the generation of an effective cellular response14. Despite this, PvRMC-MSP1 was able to 
induce strong CD4+ and CD8+ T cells in two different strains of mice. To our knowledge, this is the first evi-
dence that a recombinant subunit protein can induce both CD4+ and CD8+ T cells able to recognize PvMSP19. 
Three factors could explain the improved cellular immunogenicity of our construct: (1) The defined P. vivax pro-
miscuous T cell epitopes, specially PvT53 and PvT19, have been shown to increase the immunogenicity of diverse 
antigens, as closely related as the P. falciparum CSP (NANP)3 repeats24, or as far as B cell epitopes of the Tau and 
Amyloid-Beta proteins related to Alzheimer disease51. (2) We have shown the ability of our chimeric proteins 
with the topology used for the design of PvRMC-MSP1 to enhance dendritic cells uptake and maturation52. (3) 
Our promiscuous T cell epitopes resemble a family of compounds that are known as cell penetrating peptides 
(CPPs)52. CPPs are linear sequences ranging between 10 and 30 amino acids that contain positively charged resi-
dues (W, R, or F) and can deliver a diverse repertoire of bioactive molecules53. Peptide uptake is enhanced by the 
interaction of positively charged residues with negatively charged membranes, resulting in endocytosis by antigen 
presenting cells54.
The CD4+ T cells induced by immunization with PvRMC-MSP1 produced higher cytokine levels than those 
induced by PvMSP119, suggesting that CD4+ T cell activation by PvRMC-MSP1 allows these cells to recognize 
both MSP119 and other conserved regions through the whole MSP1 sequence and produce a balanced cytokine 
response, an effect not achieved by the native PvMSP119. CD4+ T cell activation has been correlated with protec-
tion against blood stage P. falciparum malaria in humans undergoing a controlled challenge under chloroquine 
prophylaxis17. The ability of CD4+ T cells to produce several cytokines has been proposed as a marker of their 
effector and long-term memory potential55. In the murine P. chabaudi model, effector memory T cells are related 
with protection56, while the antibody response against MSP119 induced by central memory T cells is a vital corre-
late of protection57,58. Therefore, the balanced CD4+ activation profile obtained with PvRMC-MSP1 is a desirable 
characteristic in a blood stage vaccine candidate.
Furthermore, PvRMC-MSP1 was able to induce cytokine-producing CD8+ T cells able to recognize the 
PvMSP19 antigen and peptide pools representing the entire sequence, confirming the CD8+ recognition of 
PvMSP19. Predictions by the artificial neuronal network algorithm provided by the IEDB server59–67 suggest the 
presence of potential H2-Kb, H2-Dd and H2-Ld CD8+ T cell epitopes in the N-terminal and central regions of 
the recombinant protein. In humans, the same algorithm predicts a much larger number of CD8+ T cell epitopes 
scattered along the whole length of the recombinant PvRMC-MSP1 protein. Most of the predicted CD8+ T cell 
epitopes are restricted by the frequently found HLA-A*, few by HLA-B* and almost none by HLA-C* alleles 
(Supplementary Figure S6). A cytotoxic effect against blood stage antigens by CD8+ T cells mediating protec-
tion have been demonstrated in murine models19. In humans, P. falciparum vaccine candidates have shown that 
a CD8+ T cell response recognizing PfMSP142 can increase the patency time and reduce the infective load that 
passes from the liver into the blood, as MSP1 is expressed late in the liver stage cycle20. Consequently, a P. vivax 
vaccine able to induce CD8+ T cells like PvRMC-MSP1 should be considered a strong candidate for inducing 
multi-stage immunity.
Although several studies have shown that CD8+ T cells able to recognize blood stage Plasmodium antigens are 
related with protection, studies using the murine P. berghei ANKA model have suggested that CD8+ T cells are 
also involved in the pathogenesis of cerebral malaria. Perforin-mediated killing by CD8+ T cells68 of the endothe-
lial cells in the cerebral microvasculature damages the blood-brain barrier and is one of the most important 
events on the cerebral malaria pathogenesis69. Consistent with this finding, the depletion of CD8+ T cells reduces 
murine mortality70. Importantly, the CD8+ T cells induced by the infection with P. berghei can be antigen-specific 
and non-specific. The antigen non-specific CD8+ T cells can proliferate, show an activation phenotype, express 
granzyme B and gain CTL function71. Therefore, the pathogenesis of cerebral malaria is not dependent on the 
recognition of a single blood stage antigen by CD8+ T cells, but rather is a multifactorial event induced by the 
malarial infection. As such it cannot be considered that CD8+ T cells induced by vaccination would enhance the 
processes leading to cerebral malaria.
The 50.4% frequency of responders to PvRMC-MSP1 among the studied population is similar to other MSP1 
seroprevalence studies in different endemics areas of Brazil72–74. Other studies have proposed that only antibodies 
from patients with active P. vivax infection were able to recognize PvMSP-149, suggesting that the P. vivax natural 
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infection can induce short-lived antibodies not related to protection. In contrast, PvRMC-MSP1 recognition 
was present in patients that did not have active malaria, which could be an effect of our vaccine design strategy 
as we use well-defined T and B cell epitopes to avoid the inclusion of regions of low immunogenic potential. We 
have previously demonstrated that our constructs are better recognized by naturally infected individuals when 
compared to native proteins and can circumvent the HLA restriction associated to these antigens27,35. These char-
acteristics make our proteins not only desirable for vaccination but also useful for seroepidemiological studies.
We observed that naturally acquired antibodies against PvRMC-MSP1 exhibited a cytophilic profile. In 
P. falciparum infection, human cytophilic antibodies against MSP1 and MSP2 have been related to inhibition of 
the red blood cell invasion11. In P. vivax, an antibody profile similar to the one obtained in our study was found 
to be related to low parasitemias75,76. Anti-PvRMC-MSP1 antibodies had a higher prevalence of cytophilic anti-
bodies when compared with previous reports from symptomatic patients77, with an IgG1 prevalence of 90% and 
an IgG3 prevalence of 33.7%. Evidence of the possible PvRMC-MSP1 protective effect is also observed with the 
correlation of the production of antibodies able to recognize this vaccine candidate and the months passed since 
the previous malaria episode.
There were no associations between the PvRMC-MSP1 responses with the HLA alleles present in the popula-
tion studied. We have shown that our chimeric proteins can circumvent genetic restriction to the recognition of 
pre-erythrocytic and erythrocytic P. vivax antigens27,35. It is important to test this protein in non-human primates 
from different genetic backgrounds to confirm the induction of non-genetically restricted immune responses, a 
highly desirable characteristic for a P. vivax malaria vaccine.
The individual linkage of promiscuous T cell epitopes present in PvRMC-MSP1 to the previously defined P. 
falciparum B cell epitope (NANP)6 that constitute the repeat motif of the central region of the circumsporozoite 
protein was able to induce protective antibodies able to block P. falciparum invasion of hepatic cells in vitro24. This 
epitope is also present in PvRMC-MSP1, and we observed that ~30% of the individuals in our seroprevalence 
study have antibodies to the (NANP)6 repeats. The lower prevalence of the response against P. falciparum CS 
repeats was expected since the prevalence of P. falciparum is lower in the studied population78. However, these 
results show that a multispecies malaria vaccine is feasible and should be considered in the design of future 
RMCs.
In conclusion, we report a PvMSP1 based chimeric protein, PvRMC-MSP1, designed to express several amino 
terminal cognate promiscuous T cell epitopes. PvRMC-MSP1 was able to induce cytophilic antibodies and pre-
viously unreported CD4+ and CD8+ T cell responses against PvMSP119 in mice. The high immunogenicity of 
PvRMC-MSP1 confirms our previous reports concerning the benefits of designing chimeric proteins using such 
topology. Antibodies also recognized the chimeric protein in plasma samples collected from naturally exposed 
individuals irrespective of their HLA haplotype with an immunoglobulin profile that is related to protection. 
These characteristics make PvRMC-MSP1 a highly promising synthetically designed vaccine candidate that war-
rants further investigation in clinical models.
Methods
Design and biochemical characterization of the P. vivax chimeric MSP-1. The 861 bp pvrmc-msp1 
gene was codon optimized and synthesized by Geneart (Regensburg, Germany) (Fig. 1A,B). The pvrmc-msp1 
synthetic gene is based on the reference P. vivax Belem sequence (GenBank: XP_001614842.1) and encodes a 
chimeric protein that includes: (1) Met-Ala on the N-terminus to provide the start signal and decrease degra-
dation in E. coli, respectively. Two additional amino acids, V-D, introduced downstream as part of the cloning 
strategy (Fig. 1A). (2) Five promiscuous T cell epitopes linked in tandem, [PvT4 (N78-L97), PvT6 (F118-H137), 
PvT8 (L158-D177), PvT19 (L378-S397) and PvT53 (S1058-N1077)], which were previously reported by our group using 
peptide binding competition assays24. (3) An extended version of the P. vivax MSP119 protein fragment sequence, 
which includes two T helper epitopes present in the MSP133 protein fragment. (4) Six copies of the P. falciparum 
circumsporozoite protein repeat region, (NANP)6, were included at the C-terminus for biochemical characteri-
zation of antigenic integrity and to provide an optimal affinity purification tag. (5) GPGPG spacers were inserted 
between the described sequences to enhance antigen processing and the stability of the protein.
The pvrmc-msp1 synthetic gene was digested with restriction enzymes Nco I and Xho I, and subsequently 
cloned into the pET24d(+ ) plasmid, which results in the expression of the protein with a C-terminal (His)6-tag. 
The plasmid containing the chimeric construct was then transformed into E. coli BL21 (DE3) cells (Novagen, 
Madison WI) and protein expression was induced by the incubation with one mM IPTG for 3 hours.
The resulting 290 amino acid protein, including the 6x His-tag and two additional amino acids (L-E) intro-
duced upstream from the His-tag as part of the cloning strategy, was purified with a Ni-NTA affinity column 
according to the manufacturer’s protocol (Qiagen, Valencia, CA). After initial metal chelate purification, the 
recombinant construct was purified using analytical gel filtration chromatography. Analyses by SDS-PAGE 
showed a single band of the apparent mobility of ~31 kDa. The protein was further purified by size-exclusion 
chromatography performed on an FPLC instrument (AKTA prime Plus, GE healthcare) using a Sephadex G-75 
column.
The procedures to produce the synthetic gene encoding the P. vivax MSP119 are identical to those described 
for the production of the P. yoelii MSP119 protein9, using the pvrmc-msp1 synthetic gene described above and 
PCR amplification. PvMSP119 only contains the extended version of the P. vivax MSP119 protein fragment and 
the corresponding carboxyl terminal tags. Analyses by SDS-PAGE of the 162 amino acid protein showed a single 
band of apparent mobility of ~22 kDa (Supplementary Figure S2).
The PvRMC-MSP1 protein was analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) under non-reducing conditions on 4–20% polyacrylamide gels (Lonza, Allendale, NJ). Following 
electrophoresis, western blots were performed by blotting the proteins onto nitrocellulose membranes according 
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to standard procedures, as previously described9,26. The nitrocellulose membranes were incubated with sera sam-
ples from mice immunized with one the following synthetic peptides representing: (1) the T cell epitope PvT8 
L158-D177; (2) the T cell epitope PvT19 L378-S397; (3) the T cell epitope PvT4 N78-L97; or (4) the monoclonal anti-
body 2A10, which recognizes the C-terminal tag (NANP)6, obtained from the Malaria Research and Reference 
Reagent Resource Center (MR4, ATCC Manassas, VA)], (Fig. 1C). Endotoxin levels were evaluated using the 
E-Toxate Kit (Limulus amebocyte lysate), following the manufacturer’s protocol (Sigma-Aldrich, St. Louis, MO).
Synthetic Peptide Library. A library of 61 15-mer synthetic peptides, overlapping by 11 residues each and 
spanning the complete PvRMC-MSP1 chimeric protein sequence without tags, was synthesized commercially 
using the multiple solid-phase technique (Sigma-Aldrich, St. Louis, MO). The peptide pools were used to char-
acterize cellular reactivity, with one set representing the sequence of the cognate T cell epitopes derived from 
the MSP1 structure included in our chimeric construct, and the other set representing the complete amino acid 
sequence of the MSP119 protein fragment (Supplementary Table S3).
Circular dichroism experiments used to determine the secondary structural elements in PvRMC- 
MSP1. The secondary structural elements present in the chimeric PvRMC-MSP1 protein were analyzed using 
a Jasco J-810 spectropolarimeter. The following conditions were used: A 5 × 10−6 M protein stock solution was 
prepared by dissolving 0.20 mg of each protein in one of two solvent solutions, either distilled deionized water 
or HPLC degree water-acetonitrile mixture in a 1:1 ratio. The solvent selected according to the solubility of each 
peptide. Following preparation of the peptide stock solution, 10 μ L of the compound stock was mixed with 300 μ l 
of 2,2,2-trifluoroethanol (TFE) in a 1.5 mL Eppendorf tube, 690 μ L of H2O was added to bring the volume up to 
1 mL. This mixture was then homogenized and transferred to a quartz cell. The circular dichroism spectrum was 
then recorded between a wavelength range of 190 and 260 nm.
The circular dichroism spectral data was processed using the spectropolarimeter software which subtracts 
the spectra from the blank solution (30% TFE in water) from the raw data and the resulting spectrum submitted 
to smoothing for a proper presentation. In addition, the spectropolarimeter software was used to processed the 
data obtained from units of millidegrees (mdeg) to molar ellipticity. The results are expressed as mean residue 
ellipticity [θ ], with units of degrees cm2 mol−1, according to the [θ ] = θ λ/(100lcn) function where θ λ is the meas-
ured ellipticity, l is the optical path-length, c is the polypeptide concentration, and n is the number of amino acid 
residues in the sequence as described elsewhere28,79.
CD data deconvolution process. Using the whole data set obtained for each compound molar ellipticity 
values, each wavelength of 0.2 nm are submitted to a subsequent deconvolution process using CDsstr80, Continll29 
and Selcon381 algorithms of CDPro (http://lamar.colostate.edu/~sreeram/CDPro/main.html). These algorithms 
allow for estimation of the secondary structural elements given experimental conditions for each polypeptide 
analyzed and presents the data as the percentages of α -helices, β -strands or random conformations (random coil) 
in their corresponding specific proportions. The secondary structure elements for alpha-helical conformations 
can be obtained by adding H(r) to H(d) values. Similarly, beta-strand elements can be deduced by adding S(r) 
to S(d) plus Trn (reverse turns) values and randomly organized elements are designed as Unrd (not-readable).
Molecular models for PvRMC-MSP1 and PvMSP119 predictions and structure quality assessment. 
Data for the PvRMC-MSP1 and PvMSP119 protein sequences, in FASTA format, was submitted to the I-Tasser 
remote server (http://zhanglab.ccmb.med.umich.edu) for constructing possible 3D models82–85. The data sets 
were coded S198249 for PvRMC-MSP1 and S198411 for the PvMSP119 fragment. For each protein, the top five 
most probable three-dimensional models of the protein sequences were obtained and their coordinates presented 
in protein data bank (PDB) format. Subsequent validation of the quality of the most probable three-dimensional 
structures was performed using the Swiss-model server (http://swissmodel.expasy.org) by inputting the previ-
ously obtained data sets from each molecule. As part of the quality criterion, the Q-mean index was also deter-
mined using the Swiss-model Q-mean server tool86–89.
Three-dimensional protein prediction images. Molecular modeling was performed using VMD 
1.8.6 software released from the Theoretical and Computational Biophysics Group at the University of Illinois at 
Urbana-Champaign (http://www.ks.uiuc.edu/Research/vmd/vmd-1.8.6)90,91.
Mice. All animal experiments and procedures were performed in accordance with guidelines and approved 
by the Emory University’s Institutional Animal Care and Use Committee. Female BALB/c (H-2d), and C57BL/6 
(H-2b) mice, 6 to 8 weeks of age, were purchased from Charles River (Wilmington, MA). The mice were 
immunized subcutaneously on days 0, 20 and 40, in the base of the tail and the interscapular area, using 20 μ g 
of PvRMC-MSP1 or PvMSP119 proteins emulsified in Montanide ISA 51 (Seppic, Fairfield, NJ). Mice in the con-
trol groups received PBS alone emulsified in the same adjuvant.
ELISA assays using murine sera samples. Antibodies elicited by immunization with PvRMC-MSP1 
or PvMSP119 in mice were determined by ELISA using Immulon 2HB plates (Thermo Scientific, Waltham, MA) 
coated with 1 μ g/ml of PvRMC-MSP1 or PvMSP119 diluted in carbonate buffer, or peptides representing the 
P. vivax promiscuous T cell epitopes in PBS as described9. Optical densities were determined using a 405 nm filter 
on a VERSAmax ELISA reader (Molecular Device Corporation, Sunnyvale, CA). The cutoff value was set at the 
highest dilution of sera resulting in an O.D. greater than three standard deviations (S.D.) above the mean obtained 
using sera from unimmunized mice. ELISA results are presented as the reciprocal of the end-point dilution.
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IgG subclass profiles were determined by ELISA. Following incubation with mouse sera, plates were washed 
and incubated for 90 minutes with biotinylated anti-mouse IgG1 or IgG2a rat mAbs (BD PharMingen, Franklin 
Lakes, NJ). Plates were washed again, and the bound antibodies were detected using horseradish peroxidase 
(HRP)-streptavidin (BD PharMingen) and H2O2/2,2-azinobis (3-ethylbenzthiazoline-6-sulfonic acid) (ABTS) 
as substrate (KPL).
The avidity of anti-PvRMC-MSP1 antibodies was assessed by a thiocyanate elution-based ELISA using sera 
samples obtained 20 days after the third immunization (day 60). The assay was conducted in the same manner 
as described above with a slight modification24. In brief, 0–10 M ammonium thiocyanate (NH4SCN) in PBS was 
added to each well after incubation with the sera dilutions. The plates were incubated at room temperature for 
15 min and then washed before the addition of the secondary anti-mouse IgG antibody. Serial dilutions of the 
sera were assayed in the presence or absence of 1 M NH4SCN to determine avidity index. For these experiments, 
the washing step before incubation with anti-mouse IgG antibody was duplicated to remove weakly bound IgG 
antibodies. The logarithms of reciprocal serum dilutions corresponding to the half-maximum absorbance value 
in curves obtained with and without NH4SCN, termed x1 and x2, were interpolated by third-degree polynomial 
regression. The avidity index is the ratio between the antilog of x1 and the antilog of x2, or simply antilog (x1− x2) 
as described by Ferreira and Katzin92.
Absorption ELISA. To test if conformational epitopes are preserved in PvRMC-MSP1, polyclonal antibod-
ies obtained from mice immunized with PvMSP119 were tested for reactivity against reduced or non-reduced 
PvRMC-MSP1 by ELISA. To remove antibodies elicited against linear epitopes the samples tested in ELISA were 
first absorbed with reduced PvRMC-MSP1 at 2 μ g/ml for 2 hours. For absorption under reducing conditions, 
PvRMC-MSP1 was initially treated with 0.05 M dithiothreitol (DTT) at 37 °C for 1 h. The reduced PvRMC-MSP1 
was then diluted in 0.1 M carbonate buffer, containing 0.05 M DTT as described93 and Immulon 2HB plates coated 
overnight. After 2 hours absorption, the samples were then tested for recognition of reduced or non-reduced 
PvRMC-MSP1 at 1 μ g/ml. To maintain the reducing conditions during the ELISA tests and avoid unspecific anti-
body binding mediated by the use of DTT, the washing buffer, blocking buffer and solvent buffers included 5 mM 
EDTA. Results are presented as a curve of mean absorbance values of four technical replicates versus antibody 
concentration.
Indirect immunofluorescence assays. Sera obtained from BALB/c and C57BL/6 mice after the third 
immunization with 20 μ g of the PvRMC-MSP1 were pooled, and the antibody reactivity against native protein 
was evaluated using indirect immunofluorescence assays. Blood was collected from a P. vivax infected Saimiri 
boliviensis monkeys (aliquot kindly provided by Dr. Mary Galinski) or a P. coatneyi infected rhesus macaques into 
CPD tubes. The blood samples were washed twice using RPMI 1640 medium and the cells adjusted to 1% hema-
tocrit. To each well of a 12-well slide (ICN Biomedicals Inc., Aurora, OH) 10 μ l of the cell suspension was added 
and slides air-dried before being stored at − 20 ° C. Following storage at − 20 ° C, parasites slides were air dried at 
room temperature and subsequently incubated with the different dilutions of mouse sera obtained after the third 
immunization diluted in PBS+ 0.2% BSA in a dark, moist chamber for 90 min. After the incubation, slides were 
washed three times with PBS containing Tween-20 (PBST), to minimize non-specific binding. Parasites were 
stained for 30 min at room temperature in a dark, moist chamber with goat anti-mice Alexa Fluor 488 (Invitrogen 
Corporation, Carlsbad, CA) at a 1:500 dilution in Evans Blue 0.4%. After staining, slides were washed three times, 
and parasite nuclei were visualized using 4′ ,6-diamidino-2-phenylinodole dihydrochloride (DAPI) included in 
the anti-fade mounting medium Prolong (Life Technologies, Grand Island, NY).
Flow cytometry assays. Multiparametric flow cytometry analysis of PvRMC-MSP1-specific T cells was 
conducted using an eight-color panel which allowed for simultaneous analysis of IL-2, IFN-γ , and TNF-α at the 
single-cell level in T cells derived from splenocytes obtained five days after the final boosting immunization. A 
library of 61 synthetic peptides representing the complete amino acid sequence of the chimeric protein without 
carboxyl terminal tags was used for ex vivo stimulation (Supplementary Table S3). Cells were stimulated for 
6 hours with peptide pools at a concentration of 2 μ g/ml per peptide or with PvRMC-MSP1 or PvMSP119 at 
2 μ g/ml at 37 °C in the presence of GolgiPlug (BD Biosciences, San Jose, CA). Cells were then incubated with Live/
Dead stain at 430 nm excitation (Life Technologies) followed by surface staining with α -CD3 (PerCP Cy5.5), 
α -CD4 (Alexa Fluor 700), and α -CD8α (APC-Cy7) for 30 min. The cells were then fixed, permeabilized, and 
stained with antibodies against IFN-γ (FITC), TNF-α (PE), and IL-2 (APC). All the monoclonal antibodies were 
obtained from BioLegend (San Diego, CA). Flow cytometry analyses were performed using an LSRII flow cytom-
eter (BD Biosciences, San Jose, CA). Data were analyzed using FlowJo V10.1 software, beginning with the selec-
tion of single cell and then the lymphocytes gated in SSC-A vs. FSC-A. Cells were then gated on the Live/Dead 
channel, and then CD3 + CD4+ and CD3 + CD8+ antigen-specific cytokine-secreting T cells were identified 
(Supplementary Figure S7). The frequency of antigen-specific cytokine-producing cells was determined by sub-
tracting the percentage of cytokine-producing T cells after incubation with medium alone from the percentage 
of cytokine-producing T cells after incubation with PvRMC-MSP1, the PvMSP119 protein, or the corresponding 
peptide pools. A threshold for a positive cytokine response was set above the background (sample incubated with 
medium alone), and samples that did not meet this requirement were set to zero.
Seroprevalence study area and volunteers. The characteristics of the study participants have been pre-
viously described27,35. Briefly, 253 individuals from the malaria endemic region of Rondonia, Brazil were included 
in this survey. P. vivax accounts for more than 70% of all malaria cases in this region35,94. During June through 
August (the period of increased malaria transmission) of 2004 (n = 202) and 2007 (n = 56) samples and survey 
data were collected. Most of the population used for this study consist of rain forest natives who have resided for 
over 25 years in the malaria-endemic region or transmigrants originating from several non-endemic regions that 
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have lived in Rondonia for more than ten years. For controls, samples from 30 individuals from Rio de Janeiro, 
a malaria non-endemic area, with no history of malaria or residence in endemic areas were used. The study 
was performed in accordance with the principles of the Declaration of Helsinki and in accordance with Good 
Clinical Practice (GCP). Review and approval of all the experimental protocols was granted by the Oswaldo Cruz 
Foundation Ethical Committee IRB No. 138/01 and 354/06 and the National Ethical Committee of Brazil.
Epidemiological survey. All the individuals who agreed to participate in our study signed an informed 
consent document formalizing their participation as volunteers. Volunteers were interviewed to record epide-
miological data. Survey data was entered into a database created with Epi Info 2002 (Centers for Disease Control 
and Prevention, Atlanta, GA).
Human blood samples and malaria diagnosis. Heparinized tubes were used to obtain plasma from 
10 ml whole blood samples. The plasma was separated from all blood samples and stored at − 20 °C before 
being shipped on dry ice to the Immunoparasitology Laboratory, IOC, Fiocruz. Diagnosis of malaria was made 
using thin and thick blood smears, stained with Wright-Giemsa stain (Sigma Chemical Co., St. Louis, USA). 
Parasitemia was determined for donors positive for malaria as the frequency of parasites (all species and stages 
present) per 200 leukocytes in the thick smear. Of the positive donors, six were positive for P. falciparum and 
eighteen were positive for P. vivax. These individuals were subsequently treated for their infection per the regimen 
recommended by the Brazilian Ministry of Health.
Human Antibodies Determination. The presence of antibodies against PvRMC-MSP1 in the plasma of 
the volunteers was assessed using ELISA as previously described27,35. Briefly, 200 ng of PvRMC-MSP1 was used to 
coat 96-well Maxisorp plates (Nunc, Rochester, NY). Plates were incubated overnight at 4 °C and washed with a 
0.05% Tween 20 solution in PBS (PBS-Tween). Plates were then blocked for 1 hour at 37 °C using 5% non-fat dry 
milk diluted in PBS-Tween (PBS-Tween-M). Plasma samples were diluted individually at 1:100 in PBS-Tween-M. 
Plasma samples were then added to the plates in duplicate and incubated for 1 hour at 37 °C. Following incuba-
tion, plates were washed four times with PBS-Tween and incubated with peroxidase-conjugated goat anti-human 
IgG (Sigma, St. Louis, MO) at 1:1000 dilution. O-phenylenediamine and hydrogen peroxide were used to reveal 
bound antibodies. The absorbance was read on Spectramax 250 ELISA reader (Molecular Devices, Sunnyvale, 
CA) using a 492 nm filter. The results for total IgG were expressed as reactivity indexes (RI) that were calculated 
as the mean optical density of tested samples divided by the mean optical density plus 3 standard deviations of 5 
non-exposed controls tested on each plate. Subjects were scored positive for serum IgG to a particular antigen if 
the RI was higher than 1.
In addition, IgG subclasses were determined in individual responders by ELISA. The following peroxidase 
conjugated monoclonal mouse anti-human antibodies were used: mouse anti-human IgG1 (hinge)-HRP (clone 
HP6001, Southern Biotechnology); mouse anti-human IgG2 (Fc)-HRP (clone HP6002, Southern Biotechnology); 
mouse anti-human IgG3 (hinge)-HRP (clone HP6050, Southern Biotechnology) and mouse anti-human IgG4 
(Fc)-HRP (clone HP6023, Southern Biotechnology). All antibodies were diluted by 1:1000. Samples were consid-
ered subclass-specific positive for each antigen when the OD values were 3 standard deviations above the mean 
OD of four non-exposed controls.
Absorption treatment ELISA. To ensure that the naturally acquired antibodies detected in ELISA were 
directed to PvRMC-MSP1 and not to the (NANP)6 tag used for biochemical characterization, we performed an 
IgG absorption ELISA protocol using a synthetic (NANP)6 peptide. Briefly, flat-bottom plates (NUNC, USA) 
were coated overnight with 5 μ g/mL of the peptide (NANP)6. After washing and blocking steps, plasma from 63 
randomly selected PvRMC-MSP1 IgG responders were added to the plates at a 1:100 dilution and incubated for 
two hours. After incubation, plasma samples were transferred to plates coated with PvRMC-MSP1 (200 ng) and 
the ELISA was performed as previously described.
HLA Genotyping of PBMCs. Whole blood samples drawn in EDTA were used to isolate genomic DNA 
by incubating samples for 1 hour at 50 °C with a mixture of 95 μ l of proteinase K (20 mg/ml) and 5 ml buffer G2 
(QIAamp DNA Blood Midi Kit; Qiagen Inc., Chatsworth, CA, USA). Following incubation, DNA was ethanol 
precipitated and collected with a glass rod and transferred into distilled water. The concentration and quality of 
DNA were assessed using a NanoDrop ND-1000 spectrometer (Thermo Fisher Scientific Inc., Waltham, MA, 
USA). Luminex xMAP technology and sequence-specific oligonucleotide probes (SSOPs) were used to determine 
HLA-DQB1 and HLA-DRB1 allelic groups within the study population. Briefly, this system is based on the use 
of probe arrays which are bound to color-coded plastic microspheres and locus specific biotinylated primers for 
HLA-DQB1 and HLA-DRB1 loci (LABType, One Lambda Inc, Canoga Park, CA, USA). Biotinylated amplicons 
were denatured to ssDNA and incubated with DNA complementary probes immobilized on fluorescently coated 
microspheres (beads). Samples were then incubated with R-phycoerythrin-conjugated streptavidin. After hybrid-
ization, the samples were analyzed using a Luminex Flow Analyzer. The HLA Visual 2.0 software (One Lambda, 
CA) analysis program deduces the HLA-DQB1 and HLA-DRB1 allelic groups.
Statistical Analysis. Statistical analysis and graphs were made using GraphPad Prism 5.0 software 
(GraphPad Software Inc., San Diego, CA). For analysis of the mouse immunogenicity studies, all ELISA titers were 
log-transformed to conform to the normality, and variance requirements of parametric testing and groups were 
compared using Student’s t-test or one-way ANOVA with post hoc Bonferroni’s multiple comparison post-test 
when suitable. Cellular responses were analyzed with Mann-Whitney tests for comparison of non-normally dis-
tributed data.
www.nature.com/scientificreports/
1 5Scientific RepoRts | 6:34527 | DOI: 10.1038/srep34527
For human data, analyses were done as previously described35 using Epi Info 2002 (CDC, Atlanta, GA), and 
GraphPad Prism 5.0 (GraphPad Software, San Diego, CA) according to the required statistical test. Differences 
in medians for the study population data were tested by non-parametric Mann–Whitney test when appropriate. 
Student’s t-test was used to compare the means of normally distributed data or normalized transformations were 
performed on raw data before testing by one-way ANOVA where appropriate. Differences in the proportions of 
the frequencies between variables were evaluated by chi-square (χ 2) test. Relationships between the RI against 
PvRMC-MSP1 and age, years of residence in the endemic area, time of residence in Rondonia, the number of 
past malaria episodes or months since last known malaria episode were assessed with Spearman’s rank correla-
tion. Allelic groups were grouped by DR status, and data were descriptively summarized using frequencies and 
percentages for all categorical variables. Overall associations of immunological responses with the alleles from 
each HLA-DRB1* and HLADQB1* loci were evaluated by comparing the allele frequencies between seronegative 
subjects and seropositive subjects using standard contingency tables. Each person contributed two observations 
to the table (one for each allele). Rare alleles, defined as those with less than five occurrences among subjects, 
were all pooled into a category labeled “other” for analysis. To evaluate global differences in allele distribution, we 
performed analyses using simulation methods as implemented in the software PASW. This approach randomly 
generates new cell counts for contingency tables under the null hypothesis of no association, while keeping the 
margins of the table fixed. We used an approach that compares each allele versus all others combined, resulting 
in multiple 262 tables, and used the maximum χ 2 statistic from this series of tables as a global test statistic (bipar-
tition). All statistical tests were two-sided, and HLA analyses were conducted using the PASW software system.
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